Thrombocytopenic Purpura Induced by Dezocine

doi:10.19803/j.1672-8629.2021.08.21

Abstract

Abstract: Objective To analyse a case of vein thrombosis induced by dezocin injection and related literatures, in order to provide references for clinical rational use of dezocin injection. Methods Based on the rare case report, the domestic and foreign reports of adverse reactions caused by dezocin before December 2019 were searched and analyzed. Results The mechanism of thromboembolism induced by dezocine in this case might be injury of endothelial cells, the change of blood components and hemodynamic abnormality. Serious adverse drug reactions reported less, which included a small amount of anaphylactic shock reports. Conclusion For the rational use of dezocine injection, the manufacturer should further monitor its risks, and revise and improve the relevant contents of the drug insert to ensure the safety of clinical medication.

Key words: dezocine, vein thrombosis, coagulant function abnormality, adverse drug reactions

CLC Number:

R917

HE Yan, ZHANG Jinwen. Thrombocytopenic Purpura Induced by Dezocine[J]. Chinese Journal of Pharmacovigilance, 2021, 18(8): 793-794.

References

[1] Tang H, Wu N, Zhang W, et al.Investigation and analysis of clinical application of dezocine and evaluation of rational drug use[J]. Chinese Medicine(中国医药), 2019, 8(14):1241-1244.
[2] Xu PY.Analysis and evaluation of adverse reactions of dezocine injection[J]. Modern Medicine and Health(现代医药卫生), 2018,22(34): 3547-3549.
[3] Yan DQ, Tang YM.Analysis of 73 cases of adverse reactions of dezocine injection[J]. Pharmaceutical and Clinical Research(药学与临床研究), 2014, 22(5): 465-467.
[4] Yu DD, Sun J, Li M, et al.Analysis of 1290 ADR/ADE cases caused by dezocine injection[J]. Chinese Pharmacy(中国药房), 2017, 26(28): 3650-3653.
[5] Fan BC.Analysis of 80 cases of adverse reactions caused by dezocine injection in orthopedics department of our hospital[J]. Chinese Pharmacy(中国药房), 2015, 26(32): 4521-4522.
[6] Qiu ZH, Ji HY, Li XM, et al.One case of mydriasis caused by sudden withdrawal of dezocine[J]. Medical guide(医药导报). 2020, 39(4):577-578.
[7] Ke XR, Wang XF.Analysis of 260 cases of adverse reactions induced by intravenous dezocine[J]. Taiwan Pharmaceutical Journal(海峡药学杂志), 2012, 10(24):271.
[8] Locniskar A, Greenblatt DJ, Zinny MA.Pharmacokineticsof dezocine, a new analgesic:effect of dose and route of administration[J]. Eur J Clin Pharmacol, 1986, 30(1):121-123.
[9] Wilson JM, Cohen RI, Kezer EA, et al.Single- and multiple- dose pharmacokinetics of dezocine in patients with acute or chronic pain[J]. J Clin Pharmacol, 2013, 35(4): 398-403.
[10] O’Brien JJ, Benfield P, Dezocine. A preliminary review of its pharmacodynamic and pharmacokinetic properties,and therapeutic efficacy[J]. Drugs, 1989, 38(2): 226-248.
[11] Liu R, Huang XP, Yeliseev A, et al.Novel molecular targets of dezocine and their clinical implications[J]. Anesthesiology, 2014, 120(3): 714-723.
[12] Zheng FY, Wu Y, Rao YF, et al.The role and case analysis of Naranjo assessment scale in the evaluation of adverse drug reactions[J]. Chinese Journal of Pharmacy(中国药学杂志), 2012, 47(8):650-652.
[13] Yang WJ, Xu X.Drug induced thromboembolism[J]. Journal of Adverse Drug Reactions(药物不良反应杂志), 2014, 16(1): 35-38.
[14] Meng SL.Analysis of adverse reactions of dezocine injection[J]. Clinical Rational Drug Use(临床合理用药), 2020, 13(1): 14.
[15] He XW, Gan JC.Clinical and pathological analysis of purpura drug eruption[J]. Chinese Journal of Dermatology and Venereology(中国皮肤性病学杂志), 2002, 16(3): 161-163.